Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Investigator: Sheetal Shroff, MD

Study Coordinator:

Status: Enrolling

ClinicalTrials.gov Number: NCT04259255

Phone:

Protocol Number: PRO00023890

Description

REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated. NCT number: NCT04259255
More to Explore